Instituto Nacional de Câncer - Brazil

Rio de Janeiro 20 580-120

0 studies enrolling now · 2 studies all time

What they study most

Nucleophosmin 1-mutated Acute Myeloid Leukemia, PD-L1 Positive, Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML — Stopped early